Several reports have shown that SUMOylation could improve the stability and enhance the expression levels of SMAD4, which not only increases TGF-β-mediated transcription, but also negatively regulates ARs in prostate cancer [14,15]. This evidence concerns the gene SMAD4 and prostate carcinoma.